This is very true. The beauty of the process is that once one trial from Brilacidin, Kevetrin, and Pruisol shows notable efficacy, then there will be no shortage of options (from JVs, to grants, sponsors, etc) to expand trials. Cellceutix is in such an interesting and compelling place right now. Namely, efficacy read outs are going to be coming for the entire pipeline in 2016, and will allow people to adjust their goals and beliefs as they read out. If you follow the current trial progression, and the current share price, and note pending events for 2016, this is a good time to buy in. It's awfully hard to understand how the pipeline's potential is baked into share price now. Some could argue it is a fair market capitalization, but I look back at Polymedix, which during their heyday with one drug alone in its pipeline delivered a higher market capitalization that Cellceutix has now. With that said, the market didn't give Polymedix much respect at the time for a number of reasons, and one of which is the extradordinarily high rate of antibiotic failures and extremely low approval percentage (single digits), but if you make it through, you will be rewarded. I think Brilacidin will make it through based on previous results, and validation will send the stock soaring. At least, that's what I like to believe. It's a great time to buy Cellceutix if you believe in the underdog. --Sam
Market Data 
Markets 
AI
